ALVO.IC Alvotech
Company Analysis
Latest News
Barclays Flips From Bear to Bull on Alvotech — But Can a Factory Fix Unlock a U.S. Biosimilar Empire?
Shares of Alvotech surged 5.25% to ISK 642.00 on September 16 after Barclays analyst Glen Santangelo reversed course on the biosimilar maker, upgrading it from...
🟢 Alvotech is trading 5.25% up today after Barclays upgrade
Alvotech is trading at ISK 642.00 (+5.25%) after a Barclays rating upgrade. - Alvotech rose on September 16, 2026, after Barclays upgraded it from Underweight...
🔴 Alvotech is trading 3.12% down today amid risk-off sentiment ahead of Tuesday’s Fed decision
Alvotech is trading 3.12% down at ISK 622 as the broader market turns risk-off ahead of Tuesday’s Federal Reserve decision. - Technology weakness, higher oil...
🔴 Alvotech is trading 4.10% down today as biotech stocks slide
Alvotech is trading at ISK 608, down -4.10%, as biotechnology stocks decline alongside the sector ETF, which is down 4.24% during the regular session. -...
🟢 Alvotech is trading 6% up today following FDA acceptance of AVT80 for review
Alvotech is trading at ISK 634 (+5.67%), driven by the FDA’s acceptance of AVT80’s biologics license application for review on August 31, 2026. - The review...
🔴 Alvotech is trading 6.03% down today with no confirmed new catalyst identified
Alvotech is trading 6.03% down at ISK 592 after a strong recent rally, with no fresh company-specific negative announcement identified for the August 26...
🔴 Alvotech is trading 4.13% down today after strong recent rally
Alvotech is trading 4.13% down at ISK 604 after a strong recent rally, with no fresh negative company-specific announcement identified to explain the August...
Alvotech Soars 20% on Lotus Deal and FDA Progress, but Can a Revenue-Light Biosimilar Maker Justify the Momentum?
Shares of Alvotech surged 20.3% to ISK 628 on August 24, as investors cheered a one-two punch: a new licensing deal with Taiwan-based Lotus Pharmaceutical and...
🟢 Alvotech is trading 16.3% up today after licensing agreement with Lotus Pharmaceutical
Alvotech is trading 16.3% up at ISK 628 after investors responded to its Lotus Pharmaceutical licensing agreement. - It covers proposed durvalumab and...
🟢 Alvotech is trading 4.44% up in pre-market
ALVO.IC is trading at $564.00, up 4.44% in pre-market.
Alvotech signs $150 million Lotus deal, targeting Imfinzi and Hemlibra markets
Alvotech and Lotus Pharmaceutical entered a strategic licensing agreement for two biosimilar candidates. The partnership covers AVT34, a biosimilar to Imfinzi...
Alvotech Surges 10% on Reaffirmed Guidance, but Can a Second-Half Recovery Justify the Optimism?
Shares of Alvotech jumped 10.8% to ISK 522.00 after management reaffirmed full-year targets and declared that production had returned to normal following...
🟢 Alvotech is trading 6.53% up today after reaffirming 2026 revenue and EBITDA guidance
Alvotech is trading at ISK 522.00, up +6.53%, after management reaffirmed 2026 revenue guidance: $650–700 million and adjusted EBITDA guidance: $180–220...
🔴 Alvotech is trading 4.29% down today after adjusted revenue and EBITDA declined
Alvotech is trading at ISK 469 (-4.29%) after August 19 H1 2026 results showed adjusted revenue falling to $211.9 million from $306.1 million and adjusted...
🟢 Alvotech is trading 4% up today ahead of H1 2026 results
Alvotech is trading at ISK 490.00 (+4.03%) ahead of its August 19 H1 2026 results and August 20 webcast. - The update highlighted FDA resubmissions for AVT05,...
🟢 Alvotech is trading 4.5% up today ahead of scheduled H1 2026 results
Alvotech is trading at ISK 492, up 4.46%, ahead of scheduled first-half 2026 results. • Shares fell to ISK 471 on August 18, 2026. • Results are scheduled...
Alvotech Rated Outperform at Evercore, Following Reduced FDA Regulatory Risks
Evercore ISI initiated coverage on Alvotech (NASDAQ:ALVO) with an outperform rating. The firm’s analysis notes that a recent Voluntary Action Indicated (VAI)...
🟢 Alvotech is trading 5.37% up
Alvotech is trading 5.37% up at ISK 510.00, with no clear company-specific announcement identified to explain the move. - The live price context is for August...
Alvotech Shares Surge 14% in Two Days Without Fresh News — Is This a Real Recovery or a Dead Cat Bounce?
Shares of Alvotech, the Iceland-headquartered biosimilar developer, rocketed 14.4% to ISK 445 on July 30, extending a two-session rally of roughly 26% from...
🟢 Alvotech extends gains 14.4% after FDA closes Reykjavik plant inspection with VAI rating
• Alvotech is trading 14.4% up at ISK 445.00, extending a sharp rebound. • The rally follows news on July 29 that the U.S. FDA closed its May 2026 inspection...